Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

<table>Visual gains and their percentages at months 1, 3, and 6. The incidences of eyes showing visual gain (1, 2, or ≥3 Snellen lines) are generally similar between the 2 dosing regimens; however, at month 3, the percentages of eyes that gained 1, 2, and ≥3 Snellen lines were greater in the 3 monthly initial dose group than in the PRN group.</table>

BioMed Research International

fig2

Figure 2

Figure 2: Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 

Figure 2 | Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 